Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze Technology; Initiation Of Study Triggered $5M Milestone Payment To Halozyme
Benzinga_Newsdesk